GelSight Unveils Sleek Next Generation Mobile 3D Measurement Device to Expand into New Industries
12.10.2021 16:00:00 EEST | Business Wire | Press release
GelSight, a pioneer in tactile imaging and sensing technology, today introduced the latest version of its GelSight Mobile™ probe, the Series 2. This new generation of GelSight’s mobile device offers a sleek form-factor that is one-third lighter and less than half the volume of its predecessor, allowing it to scan surfaces in tighter spaces, while maintaining accuracy, speed, and field of view.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211012005405/en/
GelSight Mobile™ Series 2 offers industry-leading, tactile measurement capabilities in a more compact, ergonomic package. (Photo: Business Wire)
GelSight’s technology enables digital tactile sensing with the sensitivity and resolution of human touch. Data captured by GelSight’s elastomeric tactile sensing platform leverages proprietary software and algorithms to provide detailed, accurate surface characterization that can generate significant gains in productivity both on the production floor and in the field while also reducing the costs associated with manual or tool-based visual inspection. The handheld GelSight Mobile device can be deployed on production and assembly lines to enable rapid and well documented quality assurance decisions. Dimensions of scratches, dents, hits, gaps, offset, hole diameter, and fastener flushness can be measured in high-resolution, on any surface, in seconds.
The Series 2 head size has been minimized, so it can be utilized across a wider variety of applications. This is especially critical in the automotive and aerospace industries where it can provide rapid, repeatable, non-destructive testing for manufacturing and maintenance, repair, and overhaul (MRO) of engines, fuselages, and other critical components.
The Series 2 product addresses needs in new market verticals and creates new use cases as customers experience its game-changing performance first-hand. After bringing on new CEO, Youssef Benmokhtar, in June 2021, GelSight has set its sights on industries that can benefit from fast, accurate, micron-level measurements on a wide variety of surfaces, such as the additive manufacturing and energy sectors. The company will also continue to grow its core business in automotive, aerospace, and forensics.
“We took the accuracy, speed and mobility that our customers loved about the first-generation handheld device, and incorporated that into a smaller, more user-friendly form-factor that can deliver payback value in a matter of weeks in terms of saved production time, labor costs, and scrap,” said Youssef Benmokhtar, CEO, GelSight. “The introduction of Series 2 is ushering GelSight into a new era. We are digitizing tactile sensing to unlock new opportunities for in-line and off-line quality control innovation, across industries.”
“We use the GelSight Mobile for our MRO operations, and we are delighted to now incorporate the Mobile Series 2,” said Yann Siehen of Safran Helicopter Engines. “We had the opportunity to evaluate Series 2 and have been impressed by its performance. Its compact and lightweight design will definitely increase the number of use cases and will accelerate our return on investment.”
GelSight will be demoing the new device at the 2021 NBAA Business Aviation Convention & Exhibition (NBAA-BACE) October 12-14, 2021, in Las Vegas, NV at Booth #1224 – West Hall. To schedule a meeting and demo, please reach out to sales@gelsight.com.
The GelSight Mobile Series 2 is shipping now. To learn more about demo evaluations or purchasing, please email info@gelsight.com.
To learn more about GelSight, please visit https://gelsight.com/.
About GelSight
GelSight develops portable, non-destructive elastomeric 3D imaging systems used to improve quality control processes in aerospace, automotive and other high-value industries. The proprietary technology that was invented at the Massachusetts Institute of Technology provides extremely detailed and rapid surface measurements and robotic sensing capabilities. For more information, please visit https://gelsight.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211012005405/en/
Contact information
Media
Kalyn Schieffer for GelSight
kos@anzupartners.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom